Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sanofi is initiating a Phase 1 clinical study titled ‘A Phase 1, Parallel, Randomized, Multi-center Study to Evaluate the Safety and Immunogenicity of Different LNP Formulations of mRNA Vaccines Using the RSV Monovalent Antigen in Healthy Participants 18 to 49 Years of Age.’ The study aims to assess the safety and immune response of various lipid nanoparticle (LNP) formulations of mRNA vaccines targeting the RSV pre-F antigen in healthy adults.
The intervention involves administering a single intramuscular dose of one of eight different RSV vaccine formulations to participants. These vaccines are designed to prevent respiratory syncytial virus (RSV) infections.
The study is randomized with a parallel intervention model and triple masking, meaning that participants, care providers, and investigators are unaware of which formulation is being administered. The primary goal is prevention, focusing on evaluating the safety and immune response.
The study is set to start on July 10, 2025, with primary completion expected six months later. The last update was submitted on July 16, 2025. These dates are crucial for tracking the study’s progress and potential market impact.
This study update could influence Sanofi’s stock performance and investor sentiment, as successful results may enhance Sanofi’s position in the competitive vaccine market. Investors should watch for updates as the study progresses.
The study is ongoing, with further details available on the ClinicalTrials portal.